Learn More
CD270 (HVEM) Monoclonal Antibody (eBioHVEM-122), eBioscience™, Invitrogen™
Mouse Monoclonal Antibody
$1562.00
Specifications
Antigen | CD270 (HVEM) |
---|---|
Clone | eBioHVEM-122 |
Concentration | 0.5 mg/mL |
Applications | Flow Cytometry, Western Blot |
Classification | Monoclonal |
Catalog Number | Mfr. No. | Quantity | Price | Quantity & Availability | |||||
---|---|---|---|---|---|---|---|---|---|
Catalog Number | Mfr. No. | Quantity | Price | Quantity & Availability | |||||
14-596-937
![]() |
Invitrogen™
14596937 |
2 mg |
Each of 1 for $1,562.00
|
|
|||||
Description
The eBioHVEM-122 antibody reacts with Herpes Virus Entry Mediator (HVEM, TR2), a member of the TNF-receptor superfamily. HVEM is found on most cell types, including T cells, B cells, monocytes, neutrophils and dendritic cells. This receptor was identified as a cellular mediator of herpes simplex virus (HSV) entry. Binding of HSV viral envelope glycoprotein D (gD) to this receptor protein has been shown to be part of the viral entry mechanism. The cytoplasmic region of HVEM was found to bind to several TRAF family members, which may mediate the signal transduction pathways that activate the immune response. Recent studies have shown HVEM as a unique ligand for BTLA (B and T lymphocyte attenuator). The conservation of the BTLA-HVEM interaction between mouse and human suggests that this system is an important pathway regulating lymphocyte activation and/or homeostasis in the immune response.
TNFRSF14 is a member of the TNF-receptor superfamily. TNFRSF14 was identified as a cellular mediator of herpes simplex virus (HSV) entry. Binding of HSV viral envelope glycoprotein D (gD) to TNFRSF14 has been shown to be part of the viral entry mechanism. The cytoplasmic region of TNFRSF14 was found to bind to several TRAF family members, which may mediate the signal transduction pathways that activate the immune response. Activation of the signal transduction pathway involving TNFRSF14 in T cells stimulates T cell proliferation and cytokine production, leading to inflammation and enhanced CTL-mediated tumor immunity, suggesting that these proteins may be useful as potential targets for controlling cellular immune responses. Multiple alternatively spliced transcript variants have been described, but the full-length nature of some of these TNFRSF14 variants have not been determined.Specifications
CD270 (HVEM) | |
0.5 mg/mL | |
Monoclonal | |
Liquid | |
RUO | |
PBS with 0.09% sodium azide; pH 7.2 | |
8764 | |
Primary | |
4°C | |
TNFRSF14 |
eBioHVEM-122 | |
Flow Cytometry, Western Blot | |
Unconjugated | |
Mouse | |
Human | |
Q92956 | |
IgG1 | |
Affinity chromatography | |
Antibody |
The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.